Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic to ...

UNIGE scientists developed an algorithm able to anticipate the risk of cancer metastasis and recurrence. Group of human colon ...

Chemotherapy commonly damages the intestinal lining, a well-known side effect. But this injury does not remain confined to ...

Why do some tumors spread while others remain localized? The mechanisms governing the metastatic potential of tumor cells ...

Opdivo® (nivolumab) in combination with Yervoy® (ipilimumab) has been made available within NHS Scotland for the first line treatment of adult patients with mismatch repair deficient (dMMR) or ...

In the evolving landscape of metastatic colorectal cancer, managing patients with RAS/BRAF wild-type tumors remains a ...

Dr. Thejus Jayakrishnan sat down with CURE at the 2026 ASCO Gastrointestinal Cancers Symposium to discuss research he ...

But is the combination a "viable alternative" to nivolumab and ipilimumab?

Yuman Fong, MD, discusses the evolution of colorectal liver metastases management from historical neglect to multimodal ...

Published on UNIGE scientists developed an algorithm able to anticipate the risk of cancer metastasis and recurrence. Group of human colon ...